The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1517
ISSUE 1517
March 27, 2017
Issue 1517
- Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
- Nusinersen (Spinraza) for Spinal Muscular Atrophy
- Exablate Neuro for Essential Tremor
- Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis
- Triferic for Iron Replacement
- Table: Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
March 27, 2017 (Issue: 1517)
The FDA has approved the fully human monoclonal
antibody bezlotoxumab (Zinplava – Merck) for use
with antibacterial drug treatment to reduce recurrence
of Clostridium difficile infection (CDI) in adults with
CDI at high risk for recurrence. It...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.